Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Tumor Lysis Syndrome 1Hematologic Neoplasms 1

Interventions

venetoclax 158Cytarabine 118Cyclophosphamide 111Specimen Handling 104Azacitidine 104fludarabine 91Biopsy 79Rituximab 50Methotrexate 45Daunorubicin 45fludarabine phosphate 42Vincristine 38Dexamethasone 37Magnetic Resonance Spectroscopy 36Injections 35Decitabine 35Granulocyte Colony-Stimulating Factor 32blinatumomab 31Mycophenolic Acid 30Idarubicin 30Whole-Body Irradiation 29Prednisone 28ibrutinib 27Tacrolimus 27Etoposide 27Doxorubicin 27Busulfan 27acalabrutinib 24Melphalan 24Filgrastim 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uric Acid × Other hematologic neoplasm × 90 days × Clear all
NCT04745910 2026-05-06

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

M.D. Anderson Cancer Center

Phase 4 Completed
10 enrolled
Other hematologic neoplasm

Tumor Lysis Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡